
  
    
      
        Introduction_NNP
        The_DT Pima_NNP Indians_NNPS have_VBP a_DT very_RB high_JJ prevalence_NN for_IN type_NN 2_CD
        diabetes_NN mellitus_JJ (_( or_CC non-insulin-dependent_JJ diabetes_NN
        mellitus_JJ ,_, NIDDM_NNP )_) with_IN evidence_NN of_IN strong_JJ familial_NN
        aggregation_NN [_NN 1_CD ]_NN ._. In_IN this_DT population_NN ,_, insulin_NN resistance_NN is_VBZ
        a_DT major_JJ risk_NN factor_NN for_IN the_DT development_NN of_IN the_DT disease_NN [_NN
        2_CD ]_NN ,_, and_CC maximal_NN insulin_NN action_NN (_( i_NNP ._. e_SYM ._. glucose_NN disposal_NN rate_NN
        at_IN pharmacological_JJ insulin_NN levels_NNS )_) was_VBD found_VBN to_TO be_VB
        determined_VBN by_IN a_DT co-dominantly_JJ inherited_VBN autosomal_NN gene_NN [_NN
        3_CD ]_NN ._. Initially_RB ,_, Bogardus_NNP and_CC colleagues_NNS observed_VBD an_DT
        association_NN and_CC linkage_NN between_IN insulin_NN resistance_NN and_CC red_JJ
        cell_NN antigens_NNS on_IN chromosome_NN 4_CD q_NN [_NN 4_CD ]_NN ._. After_IN the_DT analysis_NN of_IN
        128_CD sib-pairs_JJ using_VBG quantitative_JJ trait_NN sib-pair_JJ analysis_NN ,_,
        they_PRP observed_VBD a_DT significant_JJ linkage_NN between_IN maximal_NN insulin_NN
        action_NN and_CC the_DT intestinal_NN fatty_NN acid-binding_JJ protein_NN 2_CD
        (_( FABP_NNP 2_LS )_) gene_NN and_CC the_DT annexin_NN V_NNP (_( ANX_NNP 5_LS )_) gene_NN on_IN chromosome_NN 4_CD q_NN
        [_NN 5_CD ]_NN ._.
        It_PRP is_VBZ well_RB recognized_VBN that_DT fatty_NN acid_NN metabolism_NN is_VBZ
        linked_VBN to_TO insulin_NN resistance_NN [_NN 6_CD ,_, 7_CD ]_NN ._. Intestinal_NNP FABP_NNP 2_CD
        contains_VBZ a_DT single_JJ ligand_NN binding_JJ site_NN that_IN displays_VBZ a_DT high_JJ
        affinity_NN for_IN fatty_NN acid_NN [_NN 8_CD ]_NN ._. Because_IN it_PRP is_VBZ a_DT candidate_NN
        gene_NN at_IN this_DT locus_JJ ,_, a_DT search_NN for_IN a_DT mutation_NN was_VBD initiated_VBN
        and_CC an_DT Alanine_NNP (_( GCT_NNP )_) to_TO Threonine_NNP (_( ACT_NNP )_) polymorphism_NN at_IN
        codon_NN 54_CD was_VBD identified_VBN in_IN Pima_NNP Indians_NNPS [_NN 9_CD ]_NN ._. The_DT
        associations_NNS between_IN this_DT polymorphism_NN and_CC fasting_VBG insulin_NN
        concentration_NN ,_, fasting_VBG fat_JJ oxidation_NN ,_, and_CC glucose_NN uptake_NN
        during_IN a_DT hyperinsulinemic_JJ euglycemic_JJ clamp_NN were_VBD identified_VBN
        in_IN 137_CD non-diabetic_JJ Pima_NNP Indians_NNPS [_NN 9_CD ]_NN ._.
        Because_IN NIDDM_NNP is_VBZ a_DT genetic_JJ disorder_NN [_NN 10_CD ]_NN and_CC results_NNS
        from_IN an_DT imbalance_NN between_IN insulin_NN sensitivity_NN and_CC beta_NN cell_NN
        function_NN ,_, we_PRP hypothesized_VBN that_IN the_DT A_DT 54_CD T_NN polymorphism_NN of_IN the_DT
        FABP_NNP 2_CD gene_NN plays_VBZ a_DT role_NN in_IN the_DT pathogenesis_NNS of_IN insulin_NN
        resistance_NN ,_, which_WDT is_VBZ one_CD of_IN the_DT key_JJ determinants_NNS for_IN the_DT
        development_NN of_IN NIDDM_NNP [_NN 2_CD ]_NN ._. Since_IN insulin_NN sensitivity_NN is_VBZ
        affected_VBN by_IN hypertension_NN [_NN 11_CD ,_, 12_CD ]_NN and_CC abnormal_JJ glucose_NN
        tolerance_NN [_NN 2_CD ]_NN ,_, we_PRP examined_VBD the_DT relationship_NN of_IN this_DT
        polymorphism_NN with_IN insulin_NN sensitivity_NN in_IN 55_CD healthy_JJ and_CC
        normotensive_JJ Caucasians_NNP with_IN normal_JJ glucose_NN tolerance_NN ._.
      
      
        Results_NNS
        The_DT clinical_JJ features_NNS of_IN the_DT studied_VBN subjects_NNS were_VBD shown_VBN
        in_IN Table_NNP 1_CD ._. Using_VBG the_DT PCR-RFLP_NNP assay_NN ,_, we_PRP identified_VBD 24_CD AA_NN ,_,
        27_CD AT_NNP ,_, and_CC 4_CD TT_NNP subjects_NNS ._. In_IN this_DT Caucasian_NNP population_NN ,_, the_DT
        allele_NN frequency_NN was_VBD 68_CD %_NN for_IN the_DT A_DT allele_NN and_CC 32_CD %_NN for_IN the_DT T_NN
        allele_NN ._. The_DT distribution_NN of_IN genotypes_NNS was_VBD in_IN compliance_NN
        with_IN the_DT Hardy-_NNP Weinberg_NNP equilibrium_NN (_( p_NN =_SYM 0_CD ._. 8321_CD )_) ._.
        Since_IN there_EX were_VBD only_RB 4_CD TT_NNP subjects_NNS ,_, they_PRP were_VBD pooled_VBN
        with_IN the_DT AT_NNP subjects_NNS during_IN the_DT analysis_NN ._. There_EX were_VBD no_DT
        differences_NNS in_IN clinical_JJ features_NNS between_IN the_DT two_CD genotypic_JJ
        groups_NNS (_( AA_NN vs_NNS ._. AT_NNP /_NN TT_NNP )_) as_IN shown_VBN in_IN Table_NNP 2_CD ._. Although_IN the_DT
        AT_NNP /_NN TT_NNP subjects_NNS had_VBD a_DT higher_JJR fasting_VBG plasma_NN insulin_NN
        concentration_NN than_IN the_DT AA_NN subjects_NNS (_( p_NN =_SYM 0_CD ._. 0444_CD )_) ,_, no_DT
        differences_NNS were_VBD noted_VBN in_IN fasting_VBG plasma_NN glucose_NN
        concentrations_NNS and_CC postchallenged_JJ plasma_NN glucose_NN and_CC
        insulin_NN concentrations_NNS ._. We_PRP estimated_VBD insulin_NN sensitivity_NN
        (_( %_NN S_NNP )_) and_CC beta_NN cell_NN function_NN (_( %_NN B_NNP )_) using_VBG the_DT average_NN of_IN the_DT
        three_CD fasting_VBG plasma_NN glucose_NN and_CC insulin_NN concentrations_NNS ._.
        While_IN no_DT difference_NN was_VBD noted_VBN in_IN %_NN B_NNP ,_, the_DT AT_NNP /_NN TT_NNP subjects_NNS
        were_VBD more_JJR insulin_NN resistant_JJ (_( a_DT lower_JJR %_NN S_NNP )_) than_IN the_DT AA_NN
        subjects_NNS (_( p_NN =_SYM 0_CD ._. 0461_CD )_) ._.
        Since_IN a_DT higher_JJR body_NN mass_NN index_NN had_VBD been_VBN reported_VBN to_TO be_VB
        associated_VBN with_IN this_DT polymorphism_NN [_NN 13_CD ]_NN ,_, we_PRP were_VBD concerned_VBN
        that_IN the_DT observed_VBN differences_NNS could_MD be_VB the_DT result_NN of_IN other_JJ
        confounding_VBG covariates_NNS ._. A_DT multivariate_NN analysis_NN was_VBD
        performed_VBN to_TO examine_VB the_DT influence_NN of_IN this_DT polymorphism_NN and_CC
        other_JJ covariates_NNS (_( Table_NNP 3_LS )_) ._. This_DT polymorphism_NN and_CC body_NN mass_NN
        index_NN explained_VBD 28_CD ._. 7_CD %_NN of_IN the_DT variation_NN in_IN %_NN S_NNP and_CC this_DT
        polymorphism_NN was_VBD an_DT independent_JJ determinant_NN of_IN %_NN S_NNP (_( p_NN =_SYM
        0_CD ._. 0434_CD )_) ._. However_RB ,_, this_DT polymorphism_NN had_VBD no_DT impact_NN on_IN %_NN B_NNP ._.
        Age_NNP ,_, gender_NN and_CC waist_NN hip_NN ratio_NN accounted_VBD for_IN 19_CD ._. 5_LS %_NN of_IN the_DT
        variation_NN in_IN %_NN B_NNP ._.
      
      
        Discussions_NNP
        In_IN this_DT study_NN ,_, we_PRP found_VBD that_IN the_DT A_DT 54_CD T_NN polymorphism_NN of_IN
        the_DT FABP_NNP 2_CD was_VBD associated_VBN with_IN insulin_NN resistance_NN and_CC
        accounted_VBD for_IN 7_CD ._. 3_CD %_NN of_IN the_DT variation_NN in_IN %_NN S_NNP ._. Multivariate_NNP
        analysis_NN confirmed_VBD that_IN this_DT polymorphism_NN was_VBD an_DT
        independent_JJ risk_NN factor_NN for_IN insulin_NN resistance_NN ._. In_IN
        contrast_NN ,_, this_DT polymorphism_NN had_VBD no_DT impact_NN on_IN %_NN B_NNP ._. Our_PRP$
        observations_NNS confirm_VBP that_IN the_DT A_DT 54_CD T_NN polymorphism_NN of_IN the_DT
        FABP_NNP 2_CD affects_VBZ insulin_NN sensitivity_NN ,_, which_WDT was_VBD previously_RB
        reported_VBN in_IN Pima_NNP Indian_JJ and_CC Japanese_JJ populations_NNS [_NN 9_CD ,_,
        14_CD ]_NN ._.
        The_DT FABP_NNP 2_CD locus_JJ has_VBZ been_VBN studied_VBN extensively_RB ._. MNS_NNP red_JJ
        cell_NN antigens_NNS ,_, one_CD of_IN the_DT few_JJ genetic_JJ markers_NNS available_JJ at_IN
        that_DT time_NN ,_, were_VBD initially_RB found_VBN to_TO be_VB linked_VBN to_TO insulin_NN
        resistance_NN in_IN 86_CD non-diabetic_JJ Pima_NNP Indians_NNPS from_IN 31_CD nuclear_JJ
        families_NNS using_VBG a_DT sib-pair_JJ analysis_NN and_CC they_PRP were_VBD also_RB
        associated_VBN with_IN insulin_NN resistance_NN in_IN 132_CD non-diabetic_JJ Pima_NNP
        Indians_NNPS [_NN 4_CD ]_NN ._. With_IN additional_JJ families_NNS and_CC additional_JJ
        genetic_JJ markers_NNS ,_, a_DT significant_JJ linkage_NN was_VBD identified_VBN
        between_IN the_DT FABP_NNP 2_CD and_CC ANX_NNP 5_CD loci_NN on_IN chromosome_NN 4_CD q_NN with_IN
        insulin_NN resistance_NN in_IN 123_CD non-diabetic_JJ subjects_NNS from_IN 46_CD
        nuclear_JJ families_NNS [_NN 5_CD ]_NN ._. Furthermore_RB ,_, the_DT linkage_NN of_IN the_DT
        FABP_NNP 2_CD locus_JJ with_IN insulin_NN resistance_NN (_( 2_CD -_: hour_NN postchallenged_JJ
        insulin_NN concentration_NN )_) was_VBD also_RB found_VBN in_IN a_DT Mexican-_NNP American_JJ
        population_NN ,_, which_WDT is_VBZ genetically_RB related_VBN to_TO the_DT Pima_NNP
        Indians_NNPS [_NN 15_CD ]_NN ._. However_RB ,_, sib-pair_JJ analysis_NN failed_VBD to_TO detect_VB
        any_DT linkage_NN of_IN the_DT FABP_NNP 2_CD locus_JJ or_CC the_DT A_DT 54_CD T_NN polymorphism_NN
        with_IN diabetes_NN related_VBD phenotypes_NNS in_IN other_JJ ethnic_JJ groups_NNS [_NN
        16_CD ,_, 17_CD ]_NN as_IN shown_VBN in_IN Table_NNP 4_CD A_DT ._. Furthermore_RB ,_, no_DT linkage_NN was_VBD
        found_VBN between_IN the_DT FABP_NNP 2_CD locus_JJ (_( Table_NNP 4_CD B_NNP )_) and_CC diabetes_NN [_NN 18_CD ,_,
        19_CD ]_NN ,_, lipodystrophic_JJ diabetes_NN [_NN 20_CD ]_NN ,_, or_CC obesity_NN [_NN 17_CD ]_NN ._. As_IN
        shown_VBN in_IN Table_NNP 4_CD C_NNP ,_, the_DT population_NN association_NN studies_NNS of_IN
        the_DT FABP_NNP 2_CD locus_JJ with_IN diabetes_NN /_NN impaired_VBN glucose_NN tolerance_NN
        were_VBD negative_JJ in_IN UK_NNP ,_, Finnish_JJ ,_, and_CC Welsh_NNP [_NN 21_CD ]_NN and_CC Japanese_JJ
        populations_NNS [_NN 22_CD ]_NN ._. Subsequently_RB ,_, the_DT A_DT 54_CD T_NN polymorphism_NN was_VBD
        identified_VBN and_CC was_VBD found_VBN to_TO be_VB associated_VBN with_IN increased_VBN
        fatty_NN acid_NN binding_JJ protein_NN ,_, increased_VBD fat_JJ oxidation_NN and_CC
        increased_VBN insulin_NN resistance_NN in_IN the_DT Pima_NNP Indians_NNPS [_NN 9_CD ]_NN ._. The_DT
        population_NN association_NN studies_NNS of_IN the_DT A_DT 54_CD T_NN polymorphism_NN
        with_IN NIDDM_NNP [_NN 9_CD ,_, [_NN 23_CD 24_CD 25_CD ]_NN ]_NN ,_, coronary_JJ artery_NN disease_NN [_NN
        26_CD ,_, 27_CD ]_NN ,_, obesity_NN [_NN 24_CD ]_NN ,_, and_CC hypertension_NN [_NN 24_CD ]_NN were_VBD also_RB
        essentially_RB negative_JJ ._. Positive_JJ associations_NNS were_VBD mostly_RB
        observed_VBN in_IN quantitative_JJ association_NN studies_NNS as_IN shown_VBN in_IN
        Table_NNP 4_CD D_NNP ._. In_IN addition_NN to_TO the_DT original_JJ positive_JJ association_NN
        between_IN the_DT A_DT 54_CD T_NN polymorphism_NN and_CC fasting_VBG plasma_NN insulin_NN
        concentration_NN ,_, fasting_VBG fat_JJ oxidation_NN and_CC glucose_NN uptake_NN in_IN
        non-diabetic_JJ Pima_NNP Indians_NNPS [_NN 9_CD ]_NN ,_, positive_JJ association_NN was_VBD
        also_RB found_VBN with_IN obesity_NN [_NN 13_CD ,_, 14_CD ]_NN ,_, 2_CD -_: hour_NN post-challenged_JJ
        insulin_NN concentration_NN [_NN 14_CD ]_NN ,_, and_CC various_JJ lipid_NN metabolism_NN [_NN
        13_CD ,_, [_NN 28_CD 29_CD 30_CD ]_NN ]_NN ._. In_IN the_DT present_JJ study_NN ,_, we_PRP also_RB
        demonstrated_VBD a_DT positive_JJ quantitative_JJ association_NN between_IN
        this_DT polymorphism_NN and_CC %_NN S_NNP ._. However_RB ,_, numerous_JJ negative_JJ
        studies_NNS were_VBD also_RB noted_VBN [_NN 23_CD ,_, 24_CD ,_, 29_CD ,_, [_NN 31_CD 32_CD 33_CD ]_NN ]_NN ._.
        Clearly_RB there_EX is_VBZ substantial_JJ controversy_NN surrounding_VBG
        this_DT locus_JJ and_CC the_DT A_DT 54_CD T_NN polymorphism_NN in_IN the_DT pathogenesis_NNS of_IN
        insulin_NN resistance_NN and_CC T_NN 2_CD DM_NNP as_IN described_VBN above_IN ._.
        Disagreement_NNP also_RB occurred_VBD in_IN the_DT original_JJ Pima_NNP Indian_JJ
        study_NN ._. Although_IN significant_JJ linkages_NNS were_VBD identified_VBN at_IN the_DT
        FABP_NNP 2_CD locus_JJ with_IN fasting_VBG insulin_NN concentration_NN (_( p_NN =_SYM 0_CD ._. 0004_CD )_)
        and_CC with_IN glucose_NN uptake_NN (_( p_NN =_SYM 0_CD ._. 0008_CD )_) in_IN the_DT Pima_NNP Indians_NNPS [_NN
        5_CD ]_NN ,_, the_DT differences_NNS regarding_VBG the_DT A_DT 54_CD T_NN polymorphism_NN with_IN
        fasting_VBG insulin_NN concentrations_NNS (_( p_NN <_NN 0_CD ._. 04_CD )_) and_CC glucose_NN
        uptake_NN (_( p_NN <_NN 0_CD ._. 04_CD )_) were_VBD only_RB marginally_RB significant_JJ in_IN
        the_DT same_JJ population_NN [_NN 9_CD ]_NN ._. The_DT significant_JJ linkage_NN in_IN the_DT
        original_JJ sib-pair_JJ study_NN [_NN 5_CD ]_NN could_MD be_VB the_DT combined_VBN results_NNS
        of_IN a_DT highly_RB polymorphic_JJ marker_NN of_IN the_DT FABP_NNP 2_CD locus_JJ (_( 5_CD
        alleles_NNS vs_NNS ._. 2_CD alleles_NNS for_IN the_DT A_DT 54_CD T_NN polymorphism_NN )_) and_CC less_JJR
        intrafamilial_NN difference_NN in_IN insulin_NN sensitivity_NN as_IN the_DT
        result_NN of_IN familial_NN clustering_VBG of_IN insulin_NN sensitivity_NN ._. In_IN
        contrast_NN ,_, the_DT marginal_JJ difference_NN reflected_VBD a_DT very_RB modest_JJ
        influence_NN on_IN insulin_NN sensitivity_NN of_IN the_DT A_DT 54_CD T_NN polymorphism_NN
        in_IN the_DT Pima_NNP Indian_JJ population_NN ,_, which_WDT is_VBZ consistent_JJ with_IN our_PRP$
        observation_NN that_IN this_DT polymorphism_NN only_RB accounted_VBD for_IN 7_CD ._. 3_CD %_NN
        of_IN the_DT variation_NN in_IN %_NN S_NNP in_IN this_DT Caucasian_NNP population_NN ._.
        Furthermore_RB ,_, since_IN 1_LS )_) insulin_NN resistance_NN is_VBZ neither_DT
        necessary_JJ nor_CC sufficient_JJ for_IN the_DT development_NN of_IN T_NN 2_CD DM_NNP ,_, 2_LS )_)
        this_DT polymorphism_NN has_VBZ only_RB a_DT very_RB modest_JJ influence_NN on_IN
        insulin_NN sensitivity_NN ,_, and_CC 3_LS )_) beta_NN cell_NN dysfunction_NN ,_, on_IN which_WDT
        this_DT polymorphism_NN has_VBZ no_DT influence_NN in_IN the_DT present_JJ study_NN ,_,
        plays_VBZ a_DT key_JJ role_NN in_IN the_DT development_NN of_IN overt_JJ diabetes_NN [_NN 2_CD ]_NN ,_,
        the_DT population_NN association_NN studies_NNS and_CC linkage_NN studies_NNS are_VBP
        not_RB able_JJ to_TO detect_VB the_DT interaction_NN between_IN this_DT
        polymorphism_NN and_CC the_DT diabetes_NN phenotype_NN ._. In_IN contrast_NN ,_,
        quantitative_JJ studies_NNS of_IN diabetes-related_JJ phenotypes_NNS become_VBP
        more_RBR rewarding_JJ in_IN detecting_VBG a_DT polymorphism_NN of_IN a_DT very_RB modest_JJ
        effect_NN as_IN shown_VBN in_IN Table_NNP 4_CD D_NNP ._. The_DT negative_JJ quantitative_JJ
        studies_NNS could_MD be_VB the_DT result_NN of_IN other_JJ confounding_VBG factors_NNS ,_,
        such_JJ as_IN the_DT inclusion_NN of_IN diabetic_JJ ,_, impaired_VBN glucose_NN
        tolerant_NN or_CC hypertensive_JJ subjects_NNS in_IN the_DT study_NN ._. Therefore_RB ,_,
        we_PRP only_RB enrolled_VBD glucose_NN tolerant_NN and_CC normotensive_JJ subjects_NNS
        in_IN the_DT present_JJ study_NN for_IN the_DT reasons_NNS described_VBD
        previously_RB ._.
        The_DT most_RBS convincing_JJ evidence_NN that_WDT supports_VBZ the_DT A_DT 54_CD T_NN
        polymorphism_NN as_IN a_DT causal_NN mutation_NN is_VBZ from_IN a_DT functional_JJ
        study_NN of_IN mutated_VBN FABP_NNP 2_CD [_NN 9_CD ]_NN ._. FABP_NNP 2_CD plays_VBZ a_DT role_NN in_IN the_DT
        absorption_NN and_CC intracellular_NN transportation_NN of_IN dietary_JJ
        long-chain_JJ fatty_NN acids_NNS [_NN 8_CD ]_NN ._. Thr_NNP 54_CD -_: containing_VBG FABP_NNP 2_CD has_VBZ a_DT
        twofold_NN greater_JJR affinity_NN for_IN long-chain_JJ fatty_NN acids_NNS than_IN
        the_DT Ala_NNP 54_CD -_: containing_VBG FABP_NNP 2_CD [_NN 9_CD ]_NN ._. As_IN predicted_VBN by_IN the_DT
        proposed_VBN [_NN 6_CD ,_, 7_CD ]_NN and_CC subsequently_RB proven_VBN [_NN 34_CD ]_NN "_'' Randle_NNP 's_POS
        cycle_NN "_'' ,_, an_DT increased_VBN concentration_NN of_IN fatty_NN acid_NN inhibits_NNS
        glucose_NN uptake_NN in_IN muscle_NN and_CC results_NNS in_IN insulin_NN resistance_NN ._.
        Furthermore_RB ,_, two_CD interventional_NN studies_NNS showed_VBD that_IN this_DT
        A_DT 54_CD T_NN polymorphism_NN affected_VBD lipid_NN metabolism_NN during_IN
        interventions_NNS [_NN 35_CD ,_, 36_CD ]_NN ,_, as_IN shown_VBN in_IN Table_NNP 4_CD E_NNP ._.
        In_IN summary_NN ,_, we_PRP examined_VBD the_DT role_NN of_IN the_DT A_DT 54_CD T_NN
        polymorphism_NN in_IN the_DT pathogenesis_NNS of_IN insulin_NN resistance_NN in_IN
        55_CD glucose_NN tolerant_NN and_CC normotensive_JJ healthy_JJ Caucasians_NNP ._. We_PRP
        found_VBD that_IN this_DT polymorphism_NN had_VBD an_DT independent_NN ,_, but_CC very_RB
        modest_JJ influence_NN (_( 7_CD ._. 3_LS %_NN )_) on_IN insulin_NN sensitivity_NN (_( %_NN S_NNP )_) ,_, which_WDT
        was_VBD assessed_VBN by_IN the_DT HOMA_NNP ._. However_RB ,_, it_PRP had_VBD no_DT impact_NN on_IN beta_NN
        cell_NN function_NN (_( %_NN B_NNP )_) ._. To_TO our_PRP$ knowledge_NN ,_, this_DT is_VBZ the_DT very_RB
        first_JJ report_NN of_IN a_DT positive_JJ association_NN between_IN this_DT
        polymorphism_NN and_CC insulin_NN sensitivity_NN in_IN a_DT Caucasian_NNP
        population_NN ._.
      
      
        Subjects_NNP and_CC Methods_NNP
        
          Subjects_NNP
          Through_IN the_DT advertisement_NN in_IN the_DT campus_NN newspaper_NN of_IN
          this_DT institution_NN ,_, healthy_JJ subjects_NNS without_IN a_DT prior_JJ
          history_NN of_IN diabetes_NN and_CC hypertension_NN were_VBD invited_VBN to_TO
          participate_VB in_IN the_DT study_NN ._. None_NN of_IN the_DT participants_NNS were_VBD
          receiving_VBG medical_JJ treatment_NN on_IN a_DT regular_JJ basis_NN ._. Subjects_NNP
          were_VBD instructed_VBN to_TO fast_RB for_IN at_IN least_JJS 14_CD hours_NNS before_IN the_DT
          study_NN visit_NN ._. On_IN the_DT morning_NN of_IN the_DT visit_NN ,_, subjects_NNS were_VBD
          admitted_VBN to_TO the_DT General_NNP Clinical_NNP Research_NNP Center_NNP of_IN this_DT
          institution_NN as_IN outpatients_NNS ._. An_DT indwelling_VBG angiocatheter_NN
          was_VBD inserted_VBN into_IN an_DT antecubital_NN vein_NN ._. All_DT subjects_NNS had_VBD
          fasting_VBG blood_NN samples_NNS drawn_VBN at_IN -_: 15_CD ,_, -_: 10_CD ,_, and_CC -_: 5_CD minutes_NNS ._.
          A_DT blood_NN sample_NN for_IN the_DT fasting_VBG lipid_NN profile_NN was_VBD obtained_VBN
          at_IN -_: 15_CD minutes_NNS ._. Fasting_NNP plasma_NN glucose_NN and_CC insulin_NN
          concentrations_NNS were_VBD calculated_VBN as_IN the_DT average_NN of_IN the_DT
          three_CD fasting_VBG samples_NNS ._. After_IN an_DT oral_JJ administration_NN of_IN
          75_CD -_: gm_NN glucose_NN ,_, postchallenged_JJ blood_NN samples_NNS were_VBD drawn_VBN at_IN
          30_CD ,_, 60_CD ,_, 90_CD ,_, and_CC 120_CD minutes_NNS for_IN glucose_NN and_CC insulin_NN
          measurements_NNS ._. A_DT total_NN of_IN 55_CD Caucasian_NNP subjects_NNS were_VBD
          enrolled_VBN in_IN the_DT study_NN ._. They_PRP were_VBD glucose_NN tolerant_NN
          (_( fasting_VBG plasma_NN glucose_NN <_NN 6_CD ._. 1_CD mM_NN ,_, interval_NN plasma_NN
          glucose_NN <_NN 11_CD ._. 1_LS mM_NN ,_, and_CC 2_CD -_: hour_NN plasma_NN glucose_NN <_NN 7_CD ._. 8_CD
          mM_NN )_) ,_, and_CC normotensive_JJ (_( systolic_JJ blood_NN pressure_NN <_NN 140_CD
          mmHg_NN and_CC diastolic_JJ blood_NN pressure_NN <_NN 90_CD mmHg_NN )_) ._. Plasma_NNP
          glucose_NN and_CC insulin_NN concentrations_NNS were_VBD assayed_JJ as_IN
          described_VBN previously_RB [_NN 37_CD ]_NN ._. Insulin_NNP sensitivity_NN (_( %_NN S_NNP )_) and_CC
          beta-cell_JJ function_NN (_( %_NN B_NNP )_) were_VBD estimated_VBN based_VBN on_IN the_DT
          Homeostasis_NNP Model_NNP Assessment_NNP (_( HOMA_NNP )_) as_IN described_VBN
          elsewhere_RB [_NN 38_CD ,_, 39_CD ]_NN ._. They_PRP were_VBD calculated_VBN from_IN the_DT
          average_NN of_IN three_CD fasting_VBG plasma_NN glucose_NN and_CC insulin_NN
          concentrations_NNS (_( mM_NN and_CC mU_NN /_NN L_NNP ,_, respectively_RB )_) using_VBG the_DT
          following_JJ formulae_NN :_: %_NN S_NNP =_SYM 22_CD ._. 5_LS /_NN (_( insulin_NN x_SYM glucose_NN )_) and_CC
          %_NN B_NNP =_SYM 20_CD x_SYM insulin_NN /_NN (_( glucose_NN -_: 3_CD ._. 5_LS )_) ._. The_DT study_NN was_VBD
          approved_VBN by_IN the_DT Institutional_NNP Review_NNP Board_NNP and_CC written_VBN
          informed_VBN consents_NNS were_VBD obtained_VBN at_IN the_DT entry_NN of_IN the_DT study_NN
          from_IN each_DT participant_NN ._. We_PRP confirm_VBP that_IN the_DT study_NN has_VBZ
          complied_VBN with_IN the_DT recommendations_NNS of_IN the_DT Declaration_NNP of_IN
          Helsinki_NNP ._.
        
        
          Genotyping_NNP
          Genomic_NNP DNA_NNP was_VBD extracted_VBN from_IN peripheral_JJ leukocytes_NNS
          using_VBG the_DT method_NN described_VBD previously_RB [_NN 40_CD ]_NN ._. A_DT polymerase_NN
          chain_NN reaction-restriction_JJ fragment_NN length_NN polymorphism_NN
          (_( PCR-RFLP_NNP )_) assay_NN was_VBD developed_VBN for_IN genotyping_VBG ._. The_DT
          genomic_JJ DNA_NNP fragment_NN flanking_VBG the_DT A_DT 54_CD T_NN polymorphism_NN was_VBD
          amplified_VBN using_VBG two_CD primers_NNS flanking_VBG exon_NN 2_CD of_IN the_DT FABP_NNP 2_CD
          gene_NN :_: CTACCGAGTTTTCTTCCCACC_NNP and_CC
          AATTAAACCATCCAATGAAATAGAGC_NNP ._. Polymerase_NNP chain_NN reaction_NN
          (_( PCR_NNP )_) was_VBD carried_VBN out_IN in_IN an_DT 11_CD -_: μl_NN reaction_NN volume_NN
          containing_VBG 0_CD ._. 5_CD pM_NN of_IN each_DT primer_NN ,_, 0_CD ._. 2_CD mM_NN dNTP_NN ,_, 2_CD mM_NN MgCl_NNP 
          2_CD ,_, 5_CD %_NN glycerol_NN ,_, 0_CD ._. 275_CD U_NNP Taq_NNP
          polymerase_NN ,_, 50_CD mM_NN KC_NNP 1_CD ,_, 10_CD mM_NN Tris-_NNP HCl_NNP pH_NN 8_CD ._. 3_CD ,_, and_CC 0_CD ._. 1_CD μg_NN
          of_IN genomic_JJ DNA_NNP ._. The_DT region_NN of_IN interest_NN was_VBD amplified_VBN by_IN
          an_DT initial_JJ denaturation_NN at_IN 94_CD °_NN C_NNP for_IN 5_CD minutes_NNS ,_, 35_CD cycles_NNS
          of_IN denaturation_NN at_IN 94_CD °_NN C_NNP for_IN 30_CD seconds_NNS ,_, annealing_VBG at_IN 60_CD °_NN C_NNP
          for_IN 30_CD seconds_NNS ,_, and_CC extension_NN at_IN 72_CD °_NN C_NNP for_IN 30_CD seconds_NNS ,_, and_CC
          concluded_VBD with_IN a_DT final_JJ extension_NN at_IN 72_CD °_NN C_NNP for_IN 10_CD minutes_NNS ._.
          Then_RB ,_, 5_CD μl_NN of_IN the_DT PCR_NNP product_NN (_( 375_CD base_NN pairs_NNS )_) was_VBD
          digested_VBN in_IN a_DT 15_CD -_: μl_NN reaction_NN volume_NN containing_VBG 1_CD U_NNP of_IN Hha_NNP
          I_PRP (_( New_NNP England_NNP Biolabs_NNP Inc_NNP ._. ,_, Beverly_NNP ,_, Massachusetts_NNP ,_, USA_NNP )_)
          with_IN the_DT buffer_NN supplied_VBN by_IN the_DT vender_NN ._. The_DT digested_VBN PCR_NNP
          products_NNS were_VBD resolved_VBN on_IN 2_CD ._. 0_CD %_NN agarose_NN gels_NNS ._. Hha_NNP I_PRP
          digested_VBN the_DT wild_JJ type_NN ,_, Alanine_NNP (_( GCT_NNP )_) ,_, which_WDT yielded_VBD two_CD
          products_NNS ,_, 200_CD and_CC 175_CD base_NN pairs_NNS (_( A_DT allele_NN )_) ._. The_DT G_NNP to_TO A_DT
          substitution_NN (_( Threonine_NNP ,_, ACT_NNP )_) destroyed_VBD the_DT Hha_NNP I_PRP site_NN (_( T_NN
          allele_NN )_) ._.
        
        
          Statistical_NNP analysis_NN
          Variables_NNP ,_, which_WDT failed_VBD the_DT Normality_NNP test_NN ,_, were_VBD
          logarithmically_RB transformed_VBN before_IN analysis_NN ._. They_PRP were_VBD
          age_NN ,_, body_NN mass_NN index_NN ,_, waist-hip_JJ ratio_NN ,_, plasma_NN insulin_NN
          concentrations_NNS ,_, %_NN S_NNP ,_, and_CC %_NN B_NNP ._. The_DT relationship_NN between_IN the_DT
          variables_NNS and_CC parameters_NNS of_IN interest_NN (_( %_NN B_NNP or_CC %_NN S_NNP )_) was_VBD
          determined_VBN by_IN using_VBG univariate_NN analysis_NN ._. A_DT multivariate_NN
          analysis_NN using_VBG a_DT stepwise-regression_JJ strategy_NN was_VBD
          employed_VBN to_TO examine_VB the_DT effect_NN of_IN covariates_NNS on_IN the_DT
          parameter_NN of_IN interest_NN (_( %_NN S_NNP and_CC %_NN B_NNP )_) ._. The_DT continuous_JJ
          covariates_NNS were_VBD age_NN ,_, body_NN mass_NN index_NN ,_, waist-hip_JJ ratio_NN ,_,
          and_CC systolic_JJ and_CC diastolic_JJ blood_NN pressure_NN ._. The_DT
          categorical_JJ covariates_NNS were_VBD gender_NN and_CC the_DT FABP_NNP 2_CD
          polymorphism_NN ._. Backward_NNP stepwise_NN option_NN with_IN
          alpha-to-enter_JJ of_IN 0_CD ._. 10_CD and_CC alpha-to-remove_JJ of_IN 0_CD ._. 10_CD was_VBD
          employed_VBN to_TO exclude_VB covariates_NNS that_WDT had_VBD much_RB less_JJR or_CC no_DT
          influence_NN on_IN the_DT parameter_NN under_IN analysis_NN ,_, one_CD at_IN a_DT time_NN
          starting_VBG from_IN the_DT one_CD had_VBD least_JJS impact_NN ,_, which_WDT was_VBD based_VBN
          on_IN the_DT p_NN value_NN (_( the_DT highest_JJS p_NN value_NN )_) ._. Stepwise_NNP regression_NN
          analysis_NN was_VBD stopped_VBN when_WRB all_PDT the_DT p_NN values_NNS of_IN all_DT
          covariates_NNS ,_, that_WDT were_VBD examined_VBN ,_, were_VBD less_JJR than_IN 0_CD ._. 10_CD ._.
          Since_IN a_DT very_RB close_NN linear_JJ relationship_NN was_VBD noted_VBN between_IN
          systolic_JJ and_CC diastolic_JJ pressure_NN (_( r_LS 2_CD =_SYM 0_CD ._. 3586_CD ,_, p_NN <_NN
          0_CD ._. 0001_CD )_) and_CC also_RB between_IN body_NN mass_NN index_NN and_CC waist-hip_JJ
          ratio_NN (_( r_LS 2_CD =_SYM 0_CD ._. 3014_CD ,_, p_NN <_NN 0_CD ._. 0001_CD )_) ,_, they_PRP were_VBD removed_VBN
          from_IN the_DT multivariate_NN analysis_NN based_VBN on_IN their_PRP$ p_NN values_NNS as_IN
          indicated_VBN in_IN each_DT analysis_NN ._. A_DT nominal_JJ P_NN value_NN of_IN less_JJR
          than_IN 0_CD ._. 05_CD was_VBD considered_VBN significant_JJ ._. SYSTAT_NNP 8_CD ._. 0_CD for_IN
          Windows_NNP from_IN SPSS_NNP ,_, Inc_NNP ._. (_( Chicago_NNP ,_, Illinois_NNP )_) was_VBD used_VBN for_IN
          the_DT statistical_JJ analysis_NN ._.
        
      
    
  
